Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries.

Mease PJ, Liu M, Rebello S, Kang H, Yi E, Park Y, Greenberg JD.

Rheumatol Ther. 2019 Sep 16. doi: 10.1007/s40744-019-00172-9. [Epub ahead of print]

2.

Long-term, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-Based Registry.

Harrold LR, Griffith J, Zueger P, Litman HJ, Gershenson B, Islam SS, Barr CJ, Guo D, Fay J, Greenberg JD.

J Rheumatol. 2019 Aug 1. pii: jrheum.190260. doi: 10.3899/jrheum.190260. [Epub ahead of print]

3.

Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.

Mease PJ, Accortt NA, Rebello S, Etzel CJ, Harrison RW, Aras GA, Gharaibeh MMF, Greenberg JD, Collier DH.

Rheumatol Int. 2019 Sep;39(9):1547-1558. doi: 10.1007/s00296-019-04345-1. Epub 2019 Jul 18.

PMID:
31321485
4.

Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry.

Mease PJ, Etzel CJ, Huster WJ, Muram TM, Armstrong AW, Lisse JR, Rebello S, Dodge R, Murage MJ, Greenberg JD, Malatestinic WN.

RMD Open. 2019 May 24;5(1):e000867. doi: 10.1136/rmdopen-2018-000867. eCollection 2019.

5.

High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.

Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, Phillips AA, Rossi A, Coleman M, van Besien K, Shore TB.

Bone Marrow Transplant. 2019 Jun 12. doi: 10.1038/s41409-019-0587-0. [Epub ahead of print]

PMID:
31190006
6.

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.

Mease PJ, Karki C, Liu M, Li Y, Gershenson B, Feng H, Hur P, Greenberg JD.

RMD Open. 2019 Apr 24;5(1):e000880. doi: 10.1136/rmdopen-2018-000880. eCollection 2019.

7.

US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry.

Strober BE, Germino R, Guana A, Greenberg JD, Litman HJ, Guo N, Lebwohl M.

J Dermatolog Treat. 2019 Apr 29:1-9. doi: 10.1080/09546634.2019.1603361. [Epub ahead of print]

PMID:
31035822
8.

Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry.

Strober B, Greenberg JD, Karki C, Mason M, Guo N, Hur P, Zhao Y, Herrera V, Lin F, Lebwohl M.

BMJ Open. 2019 Apr 20;9(4):e027535. doi: 10.1136/bmjopen-2018-027535.

9.

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.

Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH.

PLoS One. 2019 Jan 23;14(1):e0210459. doi: 10.1371/journal.pone.0210459. eCollection 2019.

10.

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry.

Mease PJ, Palmer JB, Hur P, Strober BE, Lebwohl M, Karki C, Reed GW, Etzel CJ, Greenberg JD, Helliwell PS.

J Eur Acad Dermatol Venereol. 2019 May;33(5):886-892. doi: 10.1111/jdv.15443. Epub 2019 Mar 5.

11.

Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation.

Ljung L, Ueda P, Liao KP, Greenberg JD, Etzel CJ, Solomon DH, Askling J.

RMD Open. 2018 Dec 16;4(2):e000771. doi: 10.1136/rmdopen-2018-000771. eCollection 2018.

12.

Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.

Mease PJ, van der Heijde D, Karki C, Liu M, Park Y, Greenberg JD.

Rheumatol Ther. 2018 Dec;5(2):537-550. doi: 10.1007/s40744-018-0129-z. Epub 2018 Oct 23.

13.

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD.

J Rheumatol. 2018 Oct;45(10):1389-1396. doi: 10.3899/jrheum.171094. Epub 2018 Jul 1.

14.

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis.

Kavanaugh A, Singh R, Karki C, Etzel CJ, Kremer JM, Greenberg JD, Griffith J.

Clin Rheumatol. 2018 Aug;37(8):2275-2280. doi: 10.1007/s10067-018-4140-0. Epub 2018 Jun 4.

15.

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Palmer JB, Greenberg JD.

RMD Open. 2018 Apr 25;4(1):e000638. doi: 10.1136/rmdopen-2017-000638. eCollection 2018.

16.

Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.

Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD.

Clin Rheumatol. 2018 Sep;37(9):2331-2340. doi: 10.1007/s10067-018-4113-3. Epub 2018 Apr 25.

PMID:
29696436
17.

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry.

Mease PJ, Heijde DV, Karki C, Palmer JB, Liu M, Pandurengan R, Park Y, Greenberg JD.

Arthritis Care Res (Hoboken). 2018 Nov;70(11):1661-1670. doi: 10.1002/acr.23534. Epub 2018 Oct 8.

18.

Evaluation of a Methodologic Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data.

Curtis JR, Xie F, Chen L, Greenberg JD, Zhang J.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1541-1545. doi: 10.1002/acr.23533. Epub 2018 Sep 4.

19.

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.

Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Kremer JM, Yassine M.

Arthritis Res Ther. 2018 Jan 2;20(1):2. doi: 10.1186/s13075-017-1496-5.

20.

Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme.

Yamanaka H, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Novelli Horne L, Inoue E, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SMM, Wesby-van Swaay E, Nyberg F.

RMD Open. 2017 Oct 10;3(2):e000498. doi: 10.1136/rmdopen-2017-000498. eCollection 2017.

21.

Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.

Strober B, Karki C, Mason M, Guo N, Holmgren SH, Greenberg JD, Lebwohl M.

J Am Acad Dermatol. 2018 Feb;78(2):323-332. doi: 10.1016/j.jaad.2017.10.012. Epub 2017 Oct 16.

22.

Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.

Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ.

J Rheumatol. 2018 Jan;45(1):78-82. doi: 10.3899/jrheum.161567. Epub 2017 Oct 1.

PMID:
28966209
23.

Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis.

Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL.

Semin Arthritis Rheum. 2018 Feb;47(4):472-477. doi: 10.1016/j.semarthrit.2017.07.010. Epub 2017 Aug 2.

PMID:
28947312
24.

Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis.

Harrold LR, John A, Reed GW, Haselkorn T, Karki C, Li Y, Best J, Zlotnick S, Kremer JM, Greenberg JD.

Rheumatol Ther. 2017 Dec;4(2):405-417. doi: 10.1007/s40744-017-0081-3. Epub 2017 Sep 21.

25.

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry.

Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer JM.

Clin Rheumatol. 2017 Sep;36(9):2135-2140. doi: 10.1007/s10067-017-3742-2. Epub 2017 Jul 17.

26.

Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis.

Grönwall C, Amara K, Hardt U, Krishnamurthy A, Steen J, Engström M, Sun M, Ytterberg AJ, Zubarev RA, Scheel-Toellner D, Greenberg JD, Klareskog L, Catrina AI, Malmström V, Silverman GJ.

J Autoimmun. 2017 Nov;84:29-45. doi: 10.1016/j.jaut.2017.06.004. Epub 2017 Jun 21.

PMID:
28647488
27.

Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD.

J Rheumatol. 2017 Aug;44(8):1151-1158. doi: 10.3899/jrheum.160963. Epub 2017 Jun 15.

PMID:
28620063
28.

Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis.

Harrold LR, Reed GW, John A, Barr CJ, Soe K, Magner R, Saunders KC, Ruderman EM, Haselkorn T, Greenberg JD, Gibofsky A, Harrington JT, Kremer JM.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-387. doi: 10.1002/acr.23294. Epub 2018 Feb 6.

29.

Design characteristics of the Corrona Japan rheumatoid arthritis registry.

Yamanaka H, Kishimoto M, Pappas DA, Greenberg JD, Kremer JM, Tanaka Y.

Mod Rheumatol. 2018 Jan;28(1):95-100. doi: 10.1080/14397595.2017.1317383. Epub 2017 Apr 27.

PMID:
28448195
30.

Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1692-1699. doi: 10.1002/acr.23249.

31.

Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry.

Kavanaugh A, Keystone E, Greenberg JD, Reed GW, Griffith JM, Friedman AW, Saunders KC, Ganguli A.

Rheumatology (Oxford). 2017 Jul 1;56(7):1095-1101. doi: 10.1093/rheumatology/kex042.

PMID:
28340006
32.

Sex differences in gout characteristics: tailoring care for women and men.

Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg JD.

BMC Musculoskelet Disord. 2017 Mar 14;18(1):108. doi: 10.1186/s12891-017-1465-9.

33.

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.

Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ.

Clin Rheumatol. 2017 Apr;36(4):895-901. doi: 10.1007/s10067-017-3593-x. Epub 2017 Mar 7.

PMID:
28271234
34.

Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission.

Pelzek AJ, Grönwall C, Rosenthal P, Greenberg JD, McGeachy M, Moreland L, Rigby WFC, Silverman GJ.

Arthritis Rheumatol. 2017 Jun;69(6):1176-1186. doi: 10.1002/art.40053. Epub 2017 May 3.

35.

The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights.

Curtis JR, Chen L, Greenberg JD, Harrold L, Kilgore ML, Kremer JM, Solomon DH, Yun H.

Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):310-319. doi: 10.1002/pds.4126. Epub 2016 Dec 28.

36.

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.

Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM.

Arthritis Res Ther. 2016 Dec 1;18(1):280.

37.

Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis.

Cui J, Diogo D, Stahl EA, Canhao H, Mariette X, Greenberg JD, Okada Y, Pappas DA, Fulton RS, Tak PP, Nurmohamed MT, Lee A, Larson DE, Kurreeman F, Deluca TL, O'Laughlin M, Fronick CC, Fulton LL, Mardis ER, van der Horst-Bruinsma IE, Wolbink GJ, Gregersen PK, Kremer JM, Crusius JB, de Vries N, Huizinga TW, Fonseca JE, Miceli-Richard C, Karlson EW, Coenen MJ, Barton A, Plenge RM, Raychaudhuri S.

Arthritis Rheumatol. 2017 Apr;69(4):735-741. doi: 10.1002/art.39966.

38.

Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry.

Pappas DA, Kent JD, Greenberg JD, Mason MA, Kremer JM, Holt RJ.

Rheumatol Ther. 2015 Dec;2(2):153-164. Epub 2015 Sep 29.

39.

Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry.

Pappas DA, John A, Curtis JR, Reed GW, Karki C, Magner R, Kremer JM, Shewade A, Greenberg JD.

Rheumatol Ther. 2016 Jun;3(1):103-115. doi: 10.1007/s40744-016-0028-0. Epub 2016 Feb 8.

40.

Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry.

Curtis JR, Bharat A, Chen L, Greenberg JD, Harrold L, Kremer JM, Sommers T, Pappas D.

J Rheumatol. 2016 Jun;43(6):1027-9. doi: 10.3899/jrheum.151136. Epub 2016 May 1.

41.

Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry.

Harrold LR, Reed GW, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD.

Arthritis Care Res (Hoboken). 2016 Dec;68(12):1888-1893. doi: 10.1002/acr.22912.

42.

Implementing Policies to Enhance Physical Education and Physical Activity in Schools.

Cooper KH, Greenberg JD, Castelli DM, Barton M, Martin SB, Morrow JR Jr.

Res Q Exerc Sport. 2016 Jun;87(2):133-40. doi: 10.1080/02701367.2016.1164009. Epub 2016 Apr 21.

PMID:
27100264
43.

Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.

Michaud K, Berglind N, Franzén S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Nyberg F, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Askling J.

Ann Rheum Dis. 2016 Oct;75(10):1797-805. doi: 10.1136/annrheumdis-2015-208698. Epub 2016 Feb 8.

PMID:
26857699
44.

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.

Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD.

RMD Open. 2015 Dec 30;1(1):e000181. doi: 10.1136/rmdopen-2015-000181. eCollection 2015.

45.

Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort.

Greenberg JD, Palmer JB, Li Y, Herrera V, Tsang Y, Liao M.

J Rheumatol. 2016 Jan;43(1):88-96. doi: 10.3899/jrheum.150540. Epub 2015 Dec 1.

PMID:
26628601
46.

How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.

Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Michaud K, Nyberg F, Pappas DA, Reed G, Tanaka E, Tran TN, Verstappen SM, Yamanaka H, Wesby-van Swaay E, Symmons D.

Ann Rheum Dis. 2016 Oct;75(10):1789-96. doi: 10.1136/annrheumdis-2015-208105. Epub 2015 Nov 30.

PMID:
26621482
47.

Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry.

Strand V, Greenberg JD, Griffith J, Bao Y, Saunders KC, Garg V, Li G, Ganguli A.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):914-21. doi: 10.1002/acr.22784.

48.

Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.

Yoshida K, Radner H, Mjaavatten MD, Greenberg JD, Kavanaugh A, Kishimoto M, Matsui K, Okada M, Reed G, Saeki Y, Tohma S, Kremer J, Solomon DH.

J Rheumatol. 2015 Dec;42(12):2238-46. doi: 10.3899/jrheum.150240. Epub 2015 Nov 1.

PMID:
26523025
49.

Plasma levels of interleukin-1 receptor antagonist (IL1Ra) predict radiographic progression of symptomatic knee osteoarthritis.

Attur M, Statnikov A, Samuels J, Li Z, Alekseyenko AV, Greenberg JD, Krasnokutsky S, Rybak L, Lu QA, Todd J, Zhou H, Jordan JM, Kraus VB, Aliferis CF, Abramson SB.

Osteoarthritis Cartilage. 2015 Nov;23(11):1915-24. doi: 10.1016/j.joca.2015.08.006.

50.

Supplemental Content

Loading ...
Support Center